Jeffrey Hackman Buys 15,000 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Jeffrey Hackman purchased 15,000 shares of the stock in a transaction on Monday, May 19th. The stock was acquired at an average price of C$9.77 per share, with a total value of C$146,580.00.

Fennec Pharmaceuticals Price Performance

FRX opened at C$11.34 on Wednesday. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83. Fennec Pharmaceuticals Inc. has a 52-week low of C$5.65 and a 52-week high of C$11.49. The company has a 50 day moving average of C$8.30 and a two-hundred day moving average of C$8.46. The company has a market cap of C$218.69 million, a P/E ratio of -192.10 and a beta of 0.25.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.